tiredness Press Release

Title Picture
12/08/2018 - 01:30
Novartis data demonstrates consistent efficacy and tolerability of Kisqali combination therapy in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visceral disease
Novartis's picture
Novartis
12/01/2018 - 23:31
Real-world data show Novartis drug Revolade improves outcomes for ITP patients compared to other second-line therapies
Novartis's picture
Novartis
11/20/2018 - 23:00
FDA approves new treatment for patients with acute myeloid leukemia
FDA's picture
FDA
11/16/2018 - 14:37
Novartis receives positive CHMP opinion to expand Kisqali combination therapy to all women with HR+/HER2- locally advanced or metastatic breast cancer
Novartis's picture
Novartis
11/16/2018 - 12:27
FDA approves Novartis drug Promacta for first-line SAA and grants Breakthrough Therapy designation for additional new indication
Novartis's picture
Novartis
11/16/2018 - 11:12
SleepCircle: A research-based solution for controlling the sleep rhythm
HelsinkiUniv's picture
HelsinkiUniv
11/14/2018 - 12:03
More adults are using complementary and alternative medicine in England but access is unequal, finds survey
University of Bristol's picture
University of B...
11/02/2018 - 10:49
New Survey Reveals Myelodysplastic Syndromes Leave Patients Feeling Fatigued
Celgene's picture
Celgene
10/31/2018 - 14:26
Phase III Data Showed That Venclexta Plus Gazyva Reduced The Risk Of Disease Worsening Or Death In People With Previously Untreated Chronic Lymphocytic Leukemia With Co-Morbidities
Genentech's picture
Genentech
10/14/2018 - 16:56
Genentechs Kadcyla Reduced the Risk of Disease Recurring in People With HER2-Positive Early Breast Cancer With Residual Disease After Neoadjuvant Treatment
Genentech's picture
Genentech
10/10/2018 - 17:35
Sanofi Presents 8-Year Data on Lemtrada (Alemtuzumab)
Genzyme's picture
Genzyme
10/10/2018 - 16:57
Sanofi presents new data on Aubagio (teriflunomide)
Genzyme's picture
Genzyme
10/09/2018 - 16:14
OCREVUS (Ocrelizumab) Data Show Early Initiation of Treatment Reduces Disability Progression over Five Years in Relapsing and Primary Progressive Multiple Sclerosis
Genentech's picture
Genentech
10/08/2018 - 22:11
Silva's Everton are a good bet at 8/1 to finish in the top six
Betfair's picture
Betfair
10/07/2018 - 20:17
More Than 30 Data Presentations from Sanofi Genzymes Multiple Sclerosis Franchise to Be Featured at the 34th ECTRIMS Congress
Genzyme's picture
Genzyme
10/07/2018 - 19:06
Libtayo (cemiplimab-rwlc) Data at ESMO 2018 Congress Provide New Insights in Six Tumor Types Under Investigation
Genzyme's picture
Genzyme
10/01/2018 - 13:43
Genentech to Present Five-Year OCREVUS (Ocrelizumab) Efficacy and Safety Data in Relapsing and Primary Progressive Multiple Sclerosis at ECTRIMS
Genentech's picture
Genentech
09/28/2018 - 05:43
FDA approves Libtayo (cemiplimab-rwlc) as first and only treatment for advanced cutaneous squamous cell carcinoma
Genzyme's picture
Genzyme
09/26/2018 - 19:55
A cuppa a day will keep you moving
QueenslandUniv's picture
QueenslandUniv
09/19/2018 - 13:27
Quitting junk food produces similar withdrawal-type symptoms as drug addiction
University of Michigan's picture
University of M...
09/11/2018 - 23:38
The medical condition 72 percent of Americans dont know about is stealing sleep and disrupting lives, survey shows
Flamel Technologies's picture
Flamel Technologies
09/07/2018 - 19:14
Eye movement based metric serving as an on-site test metric for time awake
HelsinkiUniv's picture
HelsinkiUniv
07/20/2018 - 00:13
Vein Health: PAD, DVT and Uterine Artery Embolization
Cone Health's picture
Cone Health
07/18/2018 - 14:25
Novartis Kisqali now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women
Novartis's picture
Novartis
07/17/2018 - 12:54
Janssen Announces U.S. FDA Approval of SYMTUZATM (D/C/F/TAF), the First and Only Complete Darunavir-Based Single-Tablet Regimen for the Treatment of HIV-1 Infection
Johnson and Johnson's picture
Johnson and Johnson
07/16/2018 - 14:17
Phase 3 CREDENCE Renal Outcomes Trial of INVOKANA (canagliflozin) is Being Stopped Early for Positive Efficacy Findings
Johnson and Johnson's picture
Johnson and Johnson
07/13/2018 - 15:57
U.S. FDA Extends Review Timeline for INVOKANA (canagliflozin) Supplemental New Drug Application
Johnson and Johnson's picture
Johnson and Johnson
07/11/2018 - 02:01
Genentech Announces Submission of Supplemental New Drug Application for Venclexta for People With Previously Untreated Acute Myeloid Leukemia who are Ineligible for Intensive Chemotherapy
Genentech's picture
Genentech
07/02/2018 - 10:53
Council helps residents live a more active and BETTER life with cancer
Cambridge City Council's picture
Cambridge City ...
06/24/2018 - 00:37
Results further characterize the safety and effectiveness of INVOKANA
Johnson and Johnson's picture
Johnson and Johnson
06/22/2018 - 23:55
nearly doubled the likelihood of clinically significant weight loss compared to GLP-1s
Johnson and Johnson's picture
Johnson and Johnson
06/13/2018 - 12:38
Patients to set agenda for heart failure research
University of Bristol's picture
University of B...
06/13/2018 - 10:15
International research team finds brain changes linked to sleep need
UTSouthwestern's picture
UTSouthwestern
06/13/2018 - 10:06
Genentech Announces New Ocrevus (Ocrelizumab) Data on Long-Term Disability Benefits in Primary Progressive Multiple Sclerosis and Initiation of two Global Studies in Progressive MS
Genentech's picture
Genentech
06/08/2018 - 10:19
Genentech Announces FDA Approval for Venclexta Plus Rituxan for People With Previously Treated Chronic Lymphocytic Leukemia
Genentech's picture
Genentech
06/08/2018 - 03:01
Featured Data Includes Findings From OBSERVE-4D the Largest Real-World Study to Evaluate the Risk of Lower Extremity Amputation and Hospitalization for Heart Failure
Johnson and Johnson's picture
Johnson and Johnson
05/29/2018 - 18:34
FDA expedites review of Novartis drug Promacta for first-line severe aplastic anemia (SAA)
Novartis's picture
Novartis
05/13/2018 - 22:20
Suffering mounts as armed groups return to Bambari
MSF's picture
MSF
05/08/2018 - 21:47
Genentech Provides Update on Phase III Study Of TECENTRIQ (Atezolizumab) and COTELLIC (Cobimetinib) in People With Heavily Pre-Treated Locally Advanced or Metastatic Colorectal Cancer
Genentech's picture
Genentech
05/08/2018 - 13:03
Vigorous exercise reduces tiredness in testicular cancer survivors
Cancer Research UK's picture
Cancer Research UK
04/30/2018 - 22:24
Avadel Launches NOCTIVA, the First and Only FDA-Approved Treatment for Nocturia Due to Nocturnal Polyuria
Flamel Technologies's picture
Flamel Technologies
04/27/2018 - 06:49
Real-World Study Shows INVOKANA (canagliflozin) 300mg Demonstrates Better Blood Glucose Control Than Farxiga (dapagliflozin) 10mg in Patients with Type 2 Diabetes
Johnson and Johnson's picture
Johnson and Johnson
04/24/2018 - 14:35
Four More Mumps Cases Identified, Bringing Total to 19
Delaware State Government's picture
Delaware State ...
04/23/2018 - 07:17
Relapsing MS Patients Who Switched to Aubagio (teriflunomide) Reported Increased Treatment Satisfaction in Two Clinical Studies
Genzyme's picture
Genzyme
04/23/2018 - 05:24
Treatment Effects Maintained over Seven Years in Patients with Relapsing Remitting Multiple Sclerosis Who Received Lemtrada (alemtuzumab) in Clinical Trials
Genzyme's picture
Genzyme
04/21/2018 - 20:37
New OCREVUS (Ocrelizumab) Data at AAN Demonstrate Significant Reductions in Disease Activity and Disability Progression in Relapsing Multiple Sclerosis
Genentech's picture
Genentech
04/14/2018 - 23:14
Genentech to Present New Data at AAN Highlighting Extensive Research for Ocrevus and Expanding Neuroscience Pipeline
Genentech's picture
Genentech
04/13/2018 - 00:32
MUMPS CASES RISE TO 15
DHSS's picture
DHSS
04/12/2018 - 03:51
INVOKANA (canagliflozin) Demonstrated Significant Renal Protective Benefits in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
Johnson and Johnson's picture
Johnson and Johnson
04/06/2018 - 13:57
DPH ANNOUNCES ADDITIONAL MUMPS CASES
DHSS's picture
DHSS
03/29/2018 - 11:10
Mumps Cases Increase to 11; Possible Link to Second Mexican Dance Event at Chase Center
Delaware State Government's picture
Delaware State ...
03/28/2018 - 11:12
Mumps Cases Increase to Nine; Possible Link to Second Mexican Dance Event at Chase Center
Delaware State Government's picture
Delaware State ...
03/23/2018 - 00:09
Shingrix approved in Europe and Japan for the prevention of shingles in adults aged 50 and over
GlaxoSmithKline's picture
GlaxoSmithKline
03/22/2018 - 14:08
DPH Investigating Mumps Outbreak After February Baile Mejicano Dance at Chase Center on the Riverfront
Delaware State Government's picture
Delaware State ...
03/11/2018 - 14:59
Late-breaking exploratory analysis from the CANVAS Program presented at the American College of Cardiologys 67
Johnson and Johnson's picture
Johnson and Johnson
03/08/2018 - 22:42
Red Devils looking to forget Palace fright
Betfair's picture
Betfair
02/05/2018 - 10:01
Mice and humans share sleep disorders - fundamental mechanisms of sleep are similar regardless of species
HelsinkiUniv's picture
HelsinkiUniv
01/26/2018 - 00:05
GSKs Shingrix receives positive opinion from the CHMP in Europe for the prevention of shingles in adults aged 50 and over
GlaxoSmithKline's picture
GlaxoSmithKline
12/11/2017 - 20:47
How to care for children with chickenpox
AAD's picture
AAD
12/10/2017 - 09:49
Phase II Data Showed Genentechs Investigational Polatuzumab Vedotin Plus Bendamustine and Rituxan (BR) Increased Complete Response Rates Compared to BR Alone in Previously Treated Aggressive Lymphoma
Genentech's picture
Genentech